Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.59 |
| ▸ | MMP13 | P45452 | 2/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | LIPE | Q05469 | 1/20 | 0.49 |
| ▸ | FPR2 | P25090 | 2/20 | 0.48 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.48 |
| ▸ | MMP12 | P39900 | 1/20 | 0.46 |
| ▸ | MMP14 | P50281 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2951108 | 0.90 | GPR119 (0.63) | GPR119MMP13MMP2LIPEHRH3 | |
| SCHEMBL6397014 | 0.86 | MMP13 (0.53) | MMP13MMP2LIPEFPR2PROKR1 | |
| SCHEMBL23410126 | 0.86 | GPR119 (0.58) | GPR119MMP13MMP2LIPEHRH3 | |
| SCHEMBL29981348 | 0.86 | GPR119 (0.58) | GPR119MMP13MMP2LIPEHRH3 | |
| SCHEMBL2302202 | 0.83 | GPR119 (0.56) | GPR119MMP13MMP2LIPECHEK2 | |
| SCHEMBL1807945 | 0.81 | GPR119 (0.57) | GPR119MMP13MMP2LIPESTS | |
| SCHEMBL6397355 | 0.81 | MMP13 (0.50) | MMP13MMP2FPR2PROKR1MMP12 | |
| SCHEMBL77291 | 0.81 | GPR119 (0.60) | GPR119MMP13LIPEHRH3CHEK2 | |
| SCHEMBL75936 | 0.80 | GPR119 (0.59) | GPR119MMP13MMP14HRH3CHEK2 | |
| SCHEMBL3849703 | 0.79 | GPR119 (0.71) | GPR119HRH3STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043533-A1 | Process for making alpha-substituted hydroxamic acids | PHARMACIA CORPORATION | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043533-A1 | Process for making alpha-substituted hydroxamic acids | HAAO, RIMKLA, ASPH | GPR119 2765/4885MMP13 104/4885MMP2 1180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.